ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSKBAHRIS..MTNORSMESMMA....MD..........*JBDM Ver 2.0.16 (1th of February 2022) - 2999001/03310760CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120221019W173deBibliographieenBibliographyfrBibliographieEP16734529.7201606212018011720181220enenen201562182841 P20150622US201562207531 P20150820US2022101920224220180425201817202209142022372022050420221019202242C07D 209/94 20060101AFI20170112BHEP A61K 31/403 20060101ALI20170112BHEP A61P 37/00 20060101ALI20170112BHEP A61P 29/00 20060101ALI20170112BHEP A61P 35/00 20060101ALI20170112BHEP A61P 9/00 20060101ALI20170112BHEP A61P 1/00 20060101ALI20170112BHEP A61P 7/00 20060101ALI20170112BHEP A61P 3/00 20060101ALI20170112BHEP A61P 5/00 20060101ALI20170112BHEP C07D 209/94 20130101 FI20160727BHEP A61P 1/00 20180101 LI20200318BHEP A61P 1/04 20180101 LI20200318BHEP A61P 1/16 20180101 LI20200318BHEP A61P 17/02 20180101 LI20200319BHEP A61P 17/06 20180101 LI20200320BHEP A61P 17/10 20180101 LI20200320BHEP A61P 19/02 20180101 LI20200320BHEP A61P 25/00 20180101 LI20200320BHEP A61P 29/00 20180101 LI20200324BHEP A61P 3/00 20180101 LI20200326BHEP A61P 35/00 20180101 LI20200327BHEP A61P 37/00 20180101 LI20200331BHEP A61P 37/02 20180101 LI20200331BHEP A61P 43/00 20180101 LI20200331BHEP A61P 5/00 20180101 LI20200331BHEP A61P 7/00 20180101 LI20200331BHEP A61P 9/00 20180101 LI20200331BHEP A61P 3/10 20180101 LI20200331BHEP C07C 279/14 20130101 LI20210922BHEP deKRISTALLINES L-ARGININSALZ VON (R) -2-(7-(4-CYCLOPENTYL-3-(TRIFLUORMETHYL) BENZYLOXY ) -1,2,3,4-TETRAHYDROCYCLO-PENTA [ B ] INDOL-3-YL) ESSIGSÄURE ZUR VERWENDUNG BEI S1P1-REZEPTOR-ASSOZIERTEN ERKRANKUNGENenCRYSTALLINE L-ARGININE SALT OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLO-PENTA[B]INDOL-3-YL)ACETIC ACID FOR USE IN S1P1 RECEPTOR-ASSOCIATED DISORDERSfrSEL L-ARGININE CRISTALLIN D'ACIDE (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMÉTHYL)BENZYLOXY)-1,2,3,4-TÉTRAHYDROCYCLO-PENTA[B]INDOL-3-YL)ACÉTIQUE POUR UNE UTILISATION DANS DES TROUBLES ASSOCIÉS AU RÉCEPTEUR DE S1P1WO-A1-2010/011316WO-A1-2011/094008NORBERT RASENACK ET AL: "Crystal habit and tableting behavior", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 244, no. 1-2, 1 September 2002 (2002-09-01), pages 45-57, XP055291502, NL ISSN: 0378-5173, DOI: 10.1016/S0378-5173(02)00296-X21178613.2393996520210609BLACKBURN, Anthony C.12633 Caminito RositaSan Diego, California 92128USCASTRO, Ryan O.8706 Elford CourtSan Diego, California 92129USHADD, Mark A.8544 Ivory Coast DriveSan Diego, California 92126USMA, You-An12820 Oakfield WayPoway, California 92064USMONTALBAN, Antonio Garrido10339 Azuaga Street No. 213San Diego, California 92129USRUETER, Jaimie Karyn9022 Westvale RoadSan Diego, California 92129USSELVEY, Lee Alani12976 Cree DrivePoway, California 92064USSHAKYA, Sagar Raj12180 Dormouse RoadSan Diego, California 92129USCARLOS, Marlon1414 Klamath DriveChula Vista, California 91913USArena Pharmaceuticals, Inc.101962549007326655235 East 42nd StreetNew York, NY 10017USMewburn Ellis LLP101783151Aurora Building CounterslipBristol BS1 6BXGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRBA20180117ME20180117MA20180117MD20180117US201603850620160621enWO201620980920161229201652